111 related articles for article (PubMed ID: 20374188)
21. Long-term treatment of N-3 PUFAS on plasma lipoprotein levels and fatty acid composition of total serum and erythrocyte lipids in hypertriglyceridemic patients.
Putadechakum S; Tanphaichitr V; Leelahagul P; Pakpeankitvatana V; Surapisitchart T; Komindr S
J Med Assoc Thai; 2005 Feb; 88(2):181-6. PubMed ID: 15962668
[TBL] [Abstract][Full Text] [Related]
22. The effect of the plasma n-3/n-6 polyunsaturated fatty acid ratio on the dietary LDL phenotype transformation - insights from the LIPGENE study.
Hartwich J; Malec MM; Partyka L; Pérez-Martinez P; Marin C; López-Miranda J; Tierney AC; Mc Monagle J; Roche HM; Defoort C; Wolkow P; Dembinska-Kieć A
Clin Nutr; 2009 Oct; 28(5):510-5. PubMed ID: 19481310
[TBL] [Abstract][Full Text] [Related]
23. The enhanced effect of atenolol on hypertension in metabolic syndrome.
Ueno N; Satou Y
Metab Syndr Relat Disord; 2011 Oct; 9(5):369-73. PubMed ID: 21644841
[TBL] [Abstract][Full Text] [Related]
24. Omega-3 fatty acids and the cardiometabolic syndrome.
Juturu V
J Cardiometab Syndr; 2008; 3(4):244-53. PubMed ID: 19040594
[TBL] [Abstract][Full Text] [Related]
25. Changes in blood pressure and renal function following subtotal parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic hyperparathyroidism.
Rostaing L; Moreau-Gaudry X; Baron E; Cisterne JM; Monroziès-Bernadet P; Durand D
Clin Nephrol; 1997 Apr; 47(4):248-55. PubMed ID: 9128792
[TBL] [Abstract][Full Text] [Related]
26. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis.
Bangalore S; Messerli FH; Franklin SS; Mancia G; Champion A; Pepine CJ
Eur Heart J; 2009 Jun; 30(11):1395-401. PubMed ID: 19351690
[TBL] [Abstract][Full Text] [Related]
27. Effects of N-3 PUFAs supplementation on insulin resistance and inflammatory biomarkers in hemodialysis patients.
Rasic-Milutinovic Z; Perunicic G; Pljesa S; Gluvic Z; Sobajic S; Djuric I; Ristic D
Ren Fail; 2007; 29(3):321-9. PubMed ID: 17497447
[TBL] [Abstract][Full Text] [Related]
28. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
29. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease.
Berrettini M; Parise P; Ricotta S; Iorio A; Peirone C; Nenci GG
Thromb Haemost; 1996 Mar; 75(3):395-400. PubMed ID: 8701396
[TBL] [Abstract][Full Text] [Related]
30. Omega-3 fatty acids and blood pressure.
Cabo J; Alonso R; Mata P
Br J Nutr; 2012 Jun; 107 Suppl 2():S195-200. PubMed ID: 22591893
[TBL] [Abstract][Full Text] [Related]
31. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
Tzotzas T; Samara M; Constantinidis T; Tziomalos K; Krassas G
Angiology; 2007; 58(1):26-33. PubMed ID: 17351155
[TBL] [Abstract][Full Text] [Related]
32. Nutritional intervention to reduce the n-6/n-3 fatty acid ratio increases adiponectin concentration and fatty acid oxidation in healthy subjects.
Guebre-Egziabher F; Rabasa-Lhoret R; Bonnet F; Bastard JP; Desage M; Skilton MR; Vidal H; Laville M
Eur J Clin Nutr; 2008 Nov; 62(11):1287-93. PubMed ID: 17700650
[TBL] [Abstract][Full Text] [Related]
33. Effect of omega 3 and omega 6 fatty acid intakes from diet and supplements on plasma fatty acid levels in the first 3 years of life.
Hoyos C; Almqvist C; Garden F; Xuan W; Oddy WH; Marks GB; Webb KL
Asia Pac J Clin Nutr; 2008; 17(4):552-7. PubMed ID: 19114389
[TBL] [Abstract][Full Text] [Related]
34. Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial.
Panchaud A; Sauty A; Kernen Y; Decosterd LA; Buclin T; Boulat O; Hug C; Pilet M; Roulet M
Clin Nutr; 2006 Jun; 25(3):418-27. PubMed ID: 16325968
[TBL] [Abstract][Full Text] [Related]
35. Change in blood pressure and 5-year risk of coronary heart disease among elderly men: the Finnish cohorts of the Seven Countries Study.
Tervahauta M; Pekkanen J; Enlund H; Nissinen A
J Hypertens; 1994 Oct; 12(10):1183-9. PubMed ID: 7836735
[TBL] [Abstract][Full Text] [Related]
36. Dietary supplementation with flaxseed oil lowers blood pressure in dyslipidaemic patients.
Paschos GK; Magkos F; Panagiotakos DB; Votteas V; Zampelas A
Eur J Clin Nutr; 2007 Oct; 61(10):1201-6. PubMed ID: 17268413
[TBL] [Abstract][Full Text] [Related]
37. Mean and yearly changes in blood pressure with age in the metabolic syndrome: the DESIR study.
Safar ME; Lange C; Blacher J; Eschwège E; Tichet J; Balkau B;
Hypertens Res; 2011 Jan; 34(1):91-7. PubMed ID: 20927113
[TBL] [Abstract][Full Text] [Related]
38. Fish meal supplementation and ambulatory blood pressure in patients with hypertension: relevance of baseline membrane fatty acid composition.
Colussi G; Catena C; Dialti V; Pezzutto F; Mos L; Sechi LA
Am J Hypertens; 2014 Mar; 27(3):471-81. PubMed ID: 24390292
[TBL] [Abstract][Full Text] [Related]
39. [Combined application of magnetolaserotherapy and polyunsaturated fatty acids for the treatment of patients with hypertensive disease].
Antoniuk MV; Kantur TA; Karaman IuK; Zhukova NV
Vopr Kurortol Fizioter Lech Fiz Kult; 2011; (1):9-13. PubMed ID: 21465774
[TBL] [Abstract][Full Text] [Related]
40. Short term omega-3 polyunsaturated fatty acid supplementation induces favorable changes in right ventricle function and diastolic filling pressure in patients with chronic heart failure; A randomized clinical trial.
Chrysohoou C; Metallinos G; Georgiopoulos G; Mendrinos D; Papanikolaou A; Magkas N; Pitsavos C; Vyssoulis G; Stefanadis C; Tousoulis D
Vascul Pharmacol; 2016 Apr; 79():43-50. PubMed ID: 26807502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
